Stent News and Research

RSS

A stent is a small mesh tube that’s used to treat narrowed or weakened arteries in the body.

You may have a stent placed in an artery as part of a procedure called angioplasty (AN-jee-oh-plas-tee). Angioplasty can restore blood flow through narrowed or blocked arteries. Stents help prevent arteries from becoming narrowed or blocked again in the months or years after treatment with angioplasty. You may also have a stent placed in a weakened artery to improve blood flow and to help prevent the artery from bursting.

Stents are usually made of metal mesh, but sometimes they’re made of fabric. Fabric stents, also called stent grafts, are used in larger arteries. Some stents are coated with medicines that are slowly and continuously released into the artery. These medicines help prevent the artery from becoming blocked again.

Three-year clinical results of Medtronic's Resolute Zotarolimus-Eluting Coronary Stent released

New clinical data released today at a major meeting of interventional cardiologists show strong and sustained efficacy and safety of the Resolute® Zotarolimus-Eluting Coronary Stent from Medtronic, Inc. (NYSE: MDT) in long-term patient follow-up.

22 Sep 2009

New sirolimus-eluting stent shows greater neointimal suppression than PES

A new type of sirolimus-eluting stent (SES) successfully showed significantly greater neointimal suppression than the paclitaxel-eluting stent (PES) with greater vessel wall integrity surrounding the stent, confirming the finding of superiority of the SES over the PES stent for the trial's primary endpoint of in-stent late loss.

22 Sep 2009

Three-year results of SPIRIT III clinical trial reaffirms safety of PROMUS and TAXUS Express stents

Boston Scientific Corporation (NYSE: BSX) today welcomed three-year results from the SPIRIT III clinical trial, which continue to reaffirm the proven long-term safety of the Company's portfolio of drug-eluting stents, including the first-generation TAXUS((R)) Express(2)(TM) Paclitaxel-Eluting Coronary Stent System and the XIENCE V(TM) (PROMUS((R))) Everolimus-Eluting Coronary Stent System.

22 Sep 2009

New wireless Fractional Flow Reserve system to evaluate blood flow blockages in the arteries

St. Jude Medical, Inc. (NYSE: STJ) today announced the first use of the PressureWire™ Aeris technology, an interventional tool which measures Fractional Flow Reserve (FFR) to evaluate the severity of blood flow blockages in the arteries. This first-to-market technology helps interventional cardiologists better determine the ideal treatment option for their patients during coronary interventions, such as stent procedures.

22 Sep 2009

Study reveals effectiveness of drug-eluting stents in treating chronic total occlusions

A multicenter study in Asia found drug-eluting stents effective with a low rate of acute complications in patients with chronic total occlusions (CTOs) undergoing PCI. Results of the study will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

22 Sep 2009

FDA approves Cordis Corporation's 2.25 mm CYPHER Stent

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world’s most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide. The new 2.25 mm CYPHER® Stent is indicated for treatment of coronary blockages in small vessels, an often difficult-to-treat situation.

22 Sep 2009

Cook Medical launches the CE Marked Zilver PTX Drug-Eluting Peripheral Stent for treating PAD

In a breakthrough development that could dramatically reduce the number of leg amputations and painful bypass graft surgeries performed annually on European patients, a first-of-its kind drug-eluting stent for a widespread form of peripheral arterial disease (PAD) is now available to physicians throughout the European Union.

21 Sep 2009

XIENCE V Everolimus Eluting Coronary Stent System exhibits its advantages over the TAXUS system

Long-term data presented today from the SPIRIT III pivotal U.S. clinical trial demonstrated that the observed clinical advantages of Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System continued to increase as compared to the TAXUS(R) Express2 Paclitaxel-Eluting Coronary Stent System (TAXUS).

21 Sep 2009

Columbia University Medical Center performs the 100th ATS 3f Aortic Bioprosthesis implant

ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced that Columbia University Medical Center has achieved 100 implants of the ATS 3f(R) Aortic Bioprosthesis. Based on the precept that 'Form Follows Function,' the ATS 3f Aortic Bioprosthesis is a revolutionary next generation stentless pericardial aortic tissue valve that is unlike any other valve.

21 Sep 2009

Better visualization of soft tissues using Toshiba's LCI

To continue its commitment to advancing medical imaging technology and improving diagnosis, Toshiba America Medical Systems, Inc. introduces Low-Contrast Imaging (LCI) for Toshiba’s InfinixTM-i systems with mid (12” x 12”) and large (12” x 16”) flat-panel detectors (FPD). Toshiba will demonstrate its low-contrast imaging capabilities at this year’s Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in San Francisco, Sept. 21 – Sept. 25, 2009 (Booth #705).

21 Sep 2009

Invatec launches a 3-dimensional distal Embolic Protection System for Carotid Artery Stenting

Invatec, a comprehensive innovator of interventional products, today introduced FiberNet®, a 3-dimensional distal Embolic Protection System (EPS) for Carotid Artery Stenting with the lowest crossing profile (0.031’’) and highest performance capabilities on the market, manufactured by Lumen Biomedical. FiberNet provides superior deliverability and can be used in vessels ranging from 3.5 to 7 mm.

21 Sep 2009

PTA balloon catheter for high pressure dilation procedures

Invatec, a comprehensive innovator of interventional products, today announced the availability of REEF HP, a PTA Balloon Catheter, ideal for use in all peripheral high pressure dilatation procedures. The “lesion-specific” design of the balloon material is particularly useful in “hard-to-dilate” situations and the availability of variable shaft lengths mean that the Reef HP is equally suited to both arteriovenous (AV) shunts (50cm shaft),and peripheral applications (80/120cm shaft).

21 Sep 2009

New self-expanding peripheral stent system launched by Invatec

Invatec, a comprehensive innovator of interventional products, today launched their latest self-expanding peripheral stent system, Maris Plus. The Maris Plus stent has a “lesion-specific” design with larger sizes to meet the clinical requirements of the iliac region. The Maris Plus becomes the sixth stent platform now marketed by Invatec for the treatment of Peripheral Arterial Disease (PAD), greatly optimizing visibility, flexibility and ease of use for the physician.

21 Sep 2009

Medtronic to showcase cardiovascular product portfolio at TCT 2009

Expecting new data on drug-eluting stents and transcatheter heart valves to feature prominently at Transcatheter Cardiovascular Therapeutics (TCT) 2009 next week in San Francisco, Medtronic, Inc. (NYSE: MDT), today announced plans to showcase its innovative cardiovascular product portfolio, technology pipeline and clinical research at the world’s premier annual meeting for interventional cardiologists.

19 Sep 2009

NovoStent completes enrollment for its SAMBA Stent and Delivery System trial

NovoStent Corporation, a privately held medical device company, today announced the completion of enrollment earlier this summer in the company’s European clinical trial evaluating the use of its SAMBATM Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease.

19 Sep 2009

Patient enrollment for PLATINUM workhorse trial completed by Boston Scientific

Boston Scientific Corporation (NYSE: BSX) today announced the completion of patient enrollment in the workhorse portion of its PLATINUM clinical program. PLATINUM is a global, randomized, pivotal controlled trial designed to support U.S. Food and Drug Administration (FDA) and Japanese Ministry of Health, Labor and Welfare (MHLW) approval of the platinum chromium PROMUS((R)) Element(TM) Everolimus-Eluting Coronary Stent System.

19 Sep 2009

Interim data from GORE PROPATEN Vascular Graft studies presented at the 2009 vascular meeting

W. L. Gore & Associates (Gore) today announced that several physicians recently presented interim data from ongoing GORE PROPATEN® Vascular Graft studies to clinical audiences at the 2009 annual vascular meeting. The conference, the premier event hosted by the Society for Vascular Surgery (SVS), was held in mid-June in Denver, Colorado. One physician reported primary patency rates as high as 100 percent for below-knee bypasses.

17 Sep 2009

Study to determine the outcomes and complications of ERCP in a community practice to appear in GIE journal

A new study from researchers in Minnesota found that endoscopic retrograde cholangiopancreatography (ERCP) performed in a community hospital setting results in complication rates that compare favorably with those of academic centers while achieving technical success at or above the performance levels recommended by the American Society for Gastrointestinal Endoscopy (ASGE)/American College of Gastroenterology (ACG) Task Force.

17 Sep 2009

Pervasis Therapeutics raises funds to support clinical development programs

Pervasis Therapeutics, Inc. today announced that it completed the initial closing of a $17 million third round of financing. The proceeds will be used primarily to support the company's ongoing clinical development programs, including PVS-10200, a biologically active therapy designed to reestablish healthy vasculature following common interventions to treat peripheral arterial disease (PAD) and potentially other conditions.

17 Sep 2009

FDA provides 510(k) marketing clearance for the FlexStent Biliary Self Expanding Stent System

Flexible Stenting Solutions Inc. (“FSS”), a leading developer of next generation peripheral arterial and biliary stents, received 510(k) clearance for the FlexStent® Biliary Self Expanding Stent System.

17 Sep 2009

Stent News and Research

Further Reading

Three-year clinical results of Medtronic's Resolute Zotarolimus-Eluting Coronary Stent released

New sirolimus-eluting stent shows greater neointimal suppression than PES

Three-year results of SPIRIT III clinical trial reaffirms safety of PROMUS and TAXUS Express stents

New wireless Fractional Flow Reserve system to evaluate blood flow blockages in the arteries

Study reveals effectiveness of drug-eluting stents in treating chronic total occlusions

FDA approves Cordis Corporation's 2.25 mm CYPHER Stent

Cook Medical launches the CE Marked Zilver PTX Drug-Eluting Peripheral Stent for treating PAD

XIENCE V Everolimus Eluting Coronary Stent System exhibits its advantages over the TAXUS system

Columbia University Medical Center performs the 100th ATS 3f Aortic Bioprosthesis implant

Better visualization of soft tissues using Toshiba's LCI

Invatec launches a 3-dimensional distal Embolic Protection System for Carotid Artery Stenting

PTA balloon catheter for high pressure dilation procedures

New self-expanding peripheral stent system launched by Invatec

Medtronic to showcase cardiovascular product portfolio at TCT 2009

NovoStent completes enrollment for its SAMBA Stent and Delivery System trial

Patient enrollment for PLATINUM workhorse trial completed by Boston Scientific

Interim data from GORE PROPATEN Vascular Graft studies presented at the 2009 vascular meeting

Study to determine the outcomes and complications of ERCP in a community practice to appear in GIE journal

Pervasis Therapeutics raises funds to support clinical development programs

FDA provides 510(k) marketing clearance for the FlexStent Biliary Self Expanding Stent System

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News